| abstract |
The present disclosure is an anti-PD-L1 capable of effectively blocking interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligands (eg, MHC class II molecules and FGL1). / Provides anti-LAG3 bispecific antibody. Bispecific antibodies can have high binding affinities for both PD-L1 protein (eg, human PD-L1 protein) and LAG3 protein (eg, human LAG3 protein). Antibodies and fragments that have specificity only for the PD-L1 or LAG3 protein, or antibodies and fragments that have additional specificity for one or more other antigens are also provided. |